Relmada Therapeutics, Inc. With a primary focus on mental health, Relmada Therapeutics aims to transform the treatment of major depressive disorder (MDD) through their ongoing Phase 3 program of REL-1017. Relmada Therapeutics offers a new approach to treating CNS disorders by harnessing the power of neural plasticity.

By understanding the potential of neural plasticity in clinical settings, they aim to unlock new patterns for the treatment of MDD and other CNS disorders. MDD affects millions of adults in the United States each year, and current antidepressant options often fall short in delivering meaningful improvements. That's why Relmada Therapeutics is conducting innovative research to provide safe, efficacious, and rapid-acting treatment options for MDD.

Their flagship product, REL-1017, is currently in Phase 3 development as a potential once-daily, oral pill that blocks hyperactive NMDA receptor channels associated with MDD. By maintaining the physiological activity of glutamate, the major excitatory neurotransmitter in the brain, REL-1017 shows promise in revolutionizing the treatment of MDD. Stay updated with Relmada Therapeutics' progress and breakthroughs in the field of CNS disorders by signing up for their alerts.

This forward-thinking brand is committed to making a significant impact on mental health and the lives of those affected by CNS disorders